Folks, what I didn't't like in last few days was in order to sell their secondndary offering, they pulled out old storees on MAIZE and SANFORD CASE of rare heart disease to hype up the stock. Totally old news, these are close to 6 months old. What that means is they had no good news to offer. We can totally right off this quarter earnings. I did buy few shares , but I am going to hold off. these new buyers are in for a rude awakening.
'Driving demand'... notice this component of the press release about the Maize Genome. Well... as I have said a few times - if the community thinks PACB's enhanced accuracy is worth the extra $ - then 'it' should be buying PACB's machines. Anytime they want to start reporting increased Sequel sales, I'm ready!!
Iso-Seq Data Supports Annotation Efforts for Key Crops Wheat and Barley Tuesday, June 27, 2017
Photo by Craig Nagy Two recent papers underscore the importance of using PacBio full-length RNA sequencing to interrogate transcriptomes for major crops. Together, these publications offer compelling evidence that information considered essential for crop improvement programs is too often missed by short-read sequencers.
A team of scientists from the Earlham Institute and other institutions report the assembly and annotation for wheat, an allohexaploid genome. From lead authors Bernardo Clavijo and Luca Venturini, senior author Matthew Clark, and collaborators, “An improved assembly and annotation of the allohexaploid wheat genome identifies complete families of agronomic genes and provides genomic evidence for chromosomal translocations” came out in Genome Research.
For this project, scientists used the Iso-Seq method of generating SMRT Sequencing data for full-length transcript isoforms using six tissue types. The results allowed the team to discover thousands of genes missed in a previous annotation and corrected thousands more existing gene models. With a much-improved annotation, the scientists were able to identify a set of disease-resistance genes, gluten protein genes that are important for baking quality, and genes associated with useful traits such as plant height and grain yield. Together with the genome assembly they produced, the team reports these are “powerful resources for trait analysis and breeding of this key global crop.”
Separately, “A chromosome conformation capture ordered sequence of the barley genome” was published in Nature by lead author Martin Mascher and senior author Nils Stein from the Leibniz Institute of Plant Genetics and Crop Plant Research and collaborators. They used Iso-Seq data as part of the annotation effort for their new barley reference genome assembly, resulting in about 40,000 high-confidence genes from a total of 16 different tissues. The scientists note that SMRT Sequencing was used to generate full-length transcript data “to support gene calling in general, and the identification of alternative splice forms in particular.” Their analysis of gene families led to finding “lineage-specific duplications of genes involved in the transport of nutrients to developing seeds and the mobilization of carbohydrates in grains.”
Learn more about using the Iso-Seq method for plant and animal genome annotation and alternative splicing identification.
Curious what any of your thoughts are on this ever getting past $20. Not trying to pump. Just trying to add and position accordingly, and get other ideas than my own that this may be worth $1B tops, which puts us around $11 and change. What would be the catalyst for this to get up to $2B+? Thanks if you have anything worthwhile on this.
Nice move! Looks like investors who bought the offering at $3.10 are now up almost 20% already. I don't agree with alot of those who discount the acumen of PACB management. They are engineers, so maybe they're just implementing the MO#$%$ plan (Mother Of All Short Squeezes), LOL! Hope I don't jinx the rally.
I must be missing something here. All these officers are exercising their stock options early. Why? Everyone seems to feel that they are putting up their own money and that would be a good thing. It could also be an ominous sign. I really hope I'm wrong for the feelings I have. I owned employee stock options during my working years and never would have considered parting with them early to take possession of the underlying stock, unless I thought the stock was to head south. That is the number 1 reason employees exercise them early. Number 2 reason is tax consequences. I'm still buying in a big way, but this doesn't seem right. Any and all views would be appreciated.
At SMRT Leiden, Improvements in Characterizing Genomes, Transcriptomes, and Methylomes Monday, June 19, 2017
Last month, we co-hosted the 2nd annual SMRT Leiden conference with Leiden University Medical Center. SMRT Leiden featured three days of excellent presentations, including one day focused on bioinformatics. If you missed it, we’ve prepared this quick recap to cover the highlights. In addition, several of the presentations are available to download, and you can check out tweets from day 1 and day 2.
The meeting kicked off with a clinical angle: Eric Schadt from the Icahn School of Medicine at Mount Sinai gave a keynote talk about capturing the clinically actionable genome. Noting that we are in an age of data explosion, Schadt presented ideas for how to take advantage of that to improve human health — and ultimately to model individual health trajectories for optimal decision-making in the clinic. At Mount Sinai, Schadt said genetic testing is becoming more comprehensive, citing examples like a pan-ethnic carrier screen and pregnancy-related testing that starts before conception and follows the infant after birth. SMRT Sequencing is important for these efforts because of its excellent accuracy and long reads, which enable phasing variants and resolving complex regions. By combining technologies, Schadt said his team improved carrier screening to deliver meaningful results to more than 60% of patients, compared to fewer than 7% with traditional testing. Schadt’s colleague Robert Sebra also gave a clinical talk, in which he said that the ideal approach will be whole genome sequencing with long reads to capture challenging genes, pseudogenes, and other important but complex elements. While that is not yet practical, he noted that previous efforts in the lab to sequence whole human genomes took a year and 1,000 SMRT Cells on the PacBio RS II; with the Sequel System, that now takes 50 SMRT Cells and can be completed in two weeks.
Two keynote presentations focused on genome evolution. Shinichi Morishita from the University of Tokyo spoke about bacterial metagenomics, for which PacBio sequencing improved the detection rate for mobile elements and methylation motifs. He also works on centromeres, for which he uses PacBio sequencing with the Hi-C method. Jason Underwood from the University of Washington presented the use of long reads to compare apes and humans in order to find elements specific to humans. His team is using SMRT Sequencing to generate high-quality primate genomes, such as the recent Susie3 assembly, and to annotate them. These projects have improved structural variation detection and increased discovery of human-specific events. Underwood said high-quality PacBio assemblies would be available in the next year or two for gibbon, bonobo, and rhesus macaque.
The Max Planck Institute’s Stefan Mundlos kicked off the afternoon with a keynote about using topologically associated domains, CRISPR, and other approaches to elucidate skeletal disease. Following that, several presentations focused on the use of SMRT Sequencing to resolve challenging regions in the human genome. Adam Ameur from Uppsala University is using PacBio sequencing for targeted and whole-genome methods to resolve repeats, low frequency mutations, and more. As part of the Swedish 1000 Genomes Project, his team has sequenced two whole genomes with SMRT Sequencing so far, finding about 20,000 structural variants in each one — 80% of which were missed by short-read sequencing. From NUI Galway, Brian McStay presented on the genomic architecture of regions on human acrocentric chromosomes. These regions are difficult to sequence due to repetitive DNA, but he was able to target and sequence them successfully with NimbleGen capture and SMRT Sequencing. Our own Tyson Clark spoke about using amplification-free targeted enrichment for analyzing genomic regions associated with repeat expansion disorders.
A number of great talks focused on plants, animals, and microbes. Felix Bemm from MPI Tübingen focused on Arabidopsis, in which structural variation was being missed with short-read sequencers. By incorporating PacBio sequencing, his team was able to explore NLR complexity; they also produced 10 platinum-grade genomes for a deep dive into structural variants. The University of Rochester’s Amanda Larracuente is studying Y chromosome dynamics in Drosophila. By adding SMRT Sequencing data to their pipeline, her team improved coverage for elusive Y genes and now have as much as 40% of the Y chromosome in contigs. Wasp parasites captured our attention in a talk from Ken Kraaijeveld at VU Amsterdam. He studied asexual and sexually reproducing parasites to understand the differences in mutation accumulation in their genomes, finding that transposable elements may play a role in reduced recombination.
From the University of Oslo, Ave Tooming-Klunderud spoke about targeted sequence capture in a cod study. Focusing on a 300 kb region of hemoglobin genes, the team analyzed eight species and optimized the sample prep protocol with barcoding, which resulted in using just nine SMRT Cells. Richard Kuo from the University of Edinburgh presented data from using the Iso-Seq method to understand chicken transcriptomes; the approach improved detection of lncRNAs, transcripts that were missed in previous annotations, and splicing diversity. Finally, Thomas Otto from the Wellcome Trust Sanger Institute gave a keynote talk about long-read sequencing of parasite genomes, with a focus on Plasmodium falciparum. Otto noted that the first assembly for this genome cost $18 million (that was back in 2002), and today on the PacBio RS II System it only takes five SMRT Cells. Because the genome has only 19% GC content, SMRT Sequencing is more successful at calling intergenic regions that can’t be mapped using short-read data.
We really enjoyed two talks about immune-related genes. Marvyn Koning from our LUMC host spoke about B cells and the adaptive immune system. Sequencing has been difficult because of the high mutation rate across many locations, but Koning developed a method called ARTISAN PCR to anchor primers in one region that didn’t change. With PacBio sequencing, the approach yields much higher accuracy than short-read sequencing. Julie Karl from the University of Wisconsin-Madison talked about sequencing the complex MHC region in macaques. For this work, SMRT Sequencing has been essential to achieve the accuracy needed for a genomic region that’s even more complex than the human MHC locus.
We were treated to some proteogenomic talks as well. In a keynote presentation, Gloria Sheynkman from the Dana-Farber Cancer Institute spoke about approaches to understand the complexity of splice diversity and the proteins they produce. One method is ORF-seq, which measures the isoforms in various functional groups and relies on SMRT Sequencing to characterize the isoforms. And NKI’s Gosia Komor presented a proteogenomic analysis of alternative splicing for a colorectal cancer biomarker study. With the Iso-Seq method, the team is building up the reference set of isoforms to find those associated with cancer risk.
Finally, our own Lance Hepler offered a look at new applications for SMRT Sequencing, including new software for detection of minor variants and structural variants and multiplexed whole genome sequencing for microbes. The new Juliet tool for characterizing minor variant frequency and pbsv for increased structural variant sensitivity will both be included in the SMRT Link 5, due to be released this summer. Hepler also noted that with the multiplexing protocol a single SMRT Cell on the Sequel System will be able to sequence up to 12 microbes with genomes of ~4.5 Mb; the protocol works for the PacBio RS II System as well.
We are thankful to all of the fantastic speakers who shared their research, for our gracious host Yahya Anvar and the entire LUMC as well as everyone who attended the event. We look forward to seeing you again next year in Leiden!
Only thing thes proves is next quarter is also bad, if they were expecting post earnings announcement a rise in stockk price they would have waited post earnings to do this sale of close to 20 million shares. Situation is hopeless, this will be in low twos by post earnings. I thinknk lot of people will be jumping the ship in am. Don't be stubborn you can sell now and buy it cheaper. This bunch in the management couldn't run a horse buggy, they are totally ignorant to the needs of investors.
Pacific Biosciences of California NASDAQ : PACB Correlation Histogram
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.8 In other words, the correlation coefficient of the other stock
Does anyone know why this stock had a come back from 7% decline today?
(AXSM) Mcap $90 M /Cash $55 M / 5x Phase 3 programs in various indications targeting huge Markets with first results in Q3 2017 =10+ BAGGER ... The next big player in the making here ! GLTA
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $90 Million Cash: $55 Million(cash runway into the first quarter of 2019.) Price:$3.90
Shares Out: 23.5 Million
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
Those who are too stupid to sell there shares after recent quarter financials deserve to lose money.